Hemophilia A Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Hemophilia A (Factor VIII Deficiency) Clinical Trials Market Report Overview
The Hemophilia A (Factor VIII Deficiency) clinical trial market research report provides an overview of the Hemophilia A clinical trials scenario. The report provides top-line data relating to the clinical trials on Hemophilia A. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
Hemophilia A Clinical Trials Market Segmentation by Regions and Countries
The key regions in the Hemophilia A clinical trials market are Europe, North America, the Middle East & Africa, Asia-Pacific, and South & Central America. As of March 2023, out of all the clinical trials conducted on Hemophilia A, the majority were conducted in Europe.
As of March 2023, in the country-wise analysis, the US has the highest number of Hemophilia A clinical trials and Spain has the highest average patient enrollment. The other countries included are the UK, Italy, Germany, France, Japan, Poland, Russia, and China.
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, Italy has the highest proportion of Hemophilia A to Hematological Disorders clinical trials as of March 2023.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Turkey has the highest proportion of Hemophilia A to Hematological Disorders trials as of March 2023.
Hemophilia A Clinical Trials Analysis by Regions, 2023 (%)
For more regional insights into the Hemophilia A clinical trials market, download a free report sample
Hemophilia A Clinical Trials Market Segmentation by Sponsor Types
The key sponsor types in the Hemophilia A clinical trials market are institution, company, and the government. Out of them, the company sponsor type dominates the Hemophilia A clinical trials market, followed by institution.
Hemophilia A Clinical Trials Market Analysis by Sponsor Types, 2023 (%)
For more sponsor type insights into the Hemophilia A clinical trials market, download a free report sample
Hemophilia A Clinical Trials Market - Competitive Landscape
The leading sponsors in the Hemophilia A clinical trials market are Bayer AG, Takeda Pharmaceutical Co Ltd, F. Hoffmann-La Roche Ltd, Pfizer Inc, CSL Ltd, and Sanofi among others. Bayer AG has conducted the highest number of Hemophilia A clinical trials as of March 2023, followed by Takeda Pharmaceutical Co Ltd and F. Hoffmann-La Roche Ltd.
Hemophilia A Clinical Trials Market Analysis by Sponsors, 2023 (%)
To know more about the leading sponsors in the Hemophilia A clinical trials market, download a free report sample
Hemophilia A Clinical Trials Market Report Overview
Key Regions | Europe, North America, The Middle East & Africa, Asia-Pacific, and South & Central America |
Key Countries | The US, Spain, the UK, Italy, Germany, France, Japan, Poland, Russia, and China |
Key Sponsor Types | Institution, Company, and Government |
Leading Sponsors | Bayer AG, Takeda Pharmaceutical Co Ltd, F. Hoffmann-La Roche Ltd, Pfizer Inc, CSL Ltd, and Sanofi |
Segments Covered in the Report
Hemophilia A Clinical Trials Regional Outlook (2023)
- Asia-Pacific
- North America
- Europe
- Middle East & Africa
- South & Central America
Hemophilia A Clinical Trials Country Outlook (2023)
- The US
- Spain
- The UK
- Italy
- Germany
- France
- Japan
- Poland
- Russia
- China
Hemophilia A Clinical Trials Sponsor Type Outlook (2023)
- Institution
- Company
- Government
Scope
- The report provides top-level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type, and End point status.
- The report reviews the top companies involved and enlists all trials (Trial title, Phase, and Status) about the company.
- The report provides all the unaccomplished trials (Terminated, Suspended, and Withdrawn) with the reason for unaccomplishment.
- The Report provides enrollment trends for the past five years.
- The report provides the latest news for the past three months.
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trial count and enrollment trends by country in the global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional, and country level
Takeda Pharmaceutical Co Ltd
F. Hoffmann-La Roche Ltd
Pfizer Inc
CSL Ltd
Sanofi
Octapharma AG
Baxter International Inc
Swedish Orphan Biovitrum AB
Grifols SA
Table of Contents
Frequently asked questions
-
Which are the key regions in the Hemophilia A clinical trials market?
The key regions in the Hemophilia A clinical trials market are Europe, North America, the Middle East & Africa, Asia-Pacific, and South & Central America.
-
Which are the key countries in the Hemophilia A clinical trials market?
The key countries in the Hemophilia A clinical trials market are the US, Spain, the UK, Italy, Germany, France, Japan, Poland, Russia, and China.
-
What are the key sponsor types in the Hemophilia A clinical trials market?
The key sponsor types in the Hemophilia A clinical trials market are institution, company, and the government.
-
Who are the leading sponsors in the Hemophilia A clinical trials market?
The leading sponsors in the Hemophilia A clinical trials market are Bayer AG, Takeda Pharmaceutical Co Ltd, F. Hoffmann-La Roche Ltd, Pfizer Inc, CSL Ltd, and Sanofi.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Hemophilia A (Factor VIII Deficiency) reports

